Sensei Biotherapeutics (FTH) Stock Price, News & Analysis

Company Overview

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development. Sensei Biotherapeutics is headquartered in the United States and has focused primarily on advancing its programs through preclinical and clinical development rather than commercial sales.

The company was founded to address challenges in cancer immunotherapy by engineering biologics that can be selectively activated in tumors. Sensei Biotherapeutics is led by an experienced management team and board with backgrounds in drug development and biotechnology, though leadership details can change over time.

Key Stats

• Today's Range: $22.83 to $28.98
• 50-Day Range: N/A
• 52-Week Range: $6.32 to $36.76
• Volume: 120,982 shs
• Average Volume: 190,486 shs
• Market Capitalization: $31.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Moderate Buy

Sensei Biotherapeutics Stock Analysis - MarketRank™

Sensei Biotherapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 37th out of 86 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sensei Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Sensei Biotherapeutics has a consensus price target of $60.00, representing about 127.3% upside from its current price of $26.39.

Amount of Analyst Coverage

Sensei Biotherapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sensei Biotherapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sensei Biotherapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sensei Biotherapeutics has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FTH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sensei Biotherapeutics does not currently pay a dividend.

Dividend Growth

Sensei Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.00

News Sentiment

Sensei Biotherapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Sensei Biotherapeutics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for FTH on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.00% of the stock of Sensei Biotherapeutics is held by insiders.

Percentage Held by Institutions

10.50% of the stock of Sensei Biotherapeutics is held by institutions.

Company Calendar

• Today: 6/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FTH
• CIK: 1829802
• Web: N/A
• Phone: (240) 243-8000
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sensei Biotherapeutics: $60.00
• High Price Target: $60.00
• Low Price Target: $60.00
• Potential Upside/Downside: +151.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($142.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -83.59%
• Return on Assets: -256.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.39
• Quick Ratio: 14.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.74 per share
• Price / Book: 1.62

Miscellaneous

• Outstanding Shares: 1,340,000
• Free Float: 1,248,000
• Market Cap: $31.96 million
• Optionable: N/A
• Beta: -0.25